contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


coegin-pharma-delivers-first-commercial-batch-of-follicopeptide-products-to-gents

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Coegin Pharma is a Swedish biotechnology company with dermacosmetic projects for hair growth and skin pigmentation, as well as drug candidates for the treatment of heart attacks and leukemia. What the projects have in common is that they are based on patented technology platforms and collaborations with researchers and academics internationally. Coegin Pharma has its headquarters in Lund.

Coegin Pharma

Coegin Pharma AB ("Coegin" or the "Company") today announces that the Company has successfully produced and delivered its first commercial batch of hair growth products based on Follicopeptide...

<div class="bequoted-body">Coegin Pharma AB ("Coegin" or the "Company") today announces that the Company has successfully produced and delivered its first commercial batch of hair growth products based on Follicopeptide® to Gents, one of the leading premium grooming retailers in the Nordic region.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;The delivered batch is intended for customers who placed pre-orders with Gents' mid November. The entire pre-order batch sold out in just a couple of days, clearly demonstrating strong consumer interest ahead of the full market launch. Following this successful pre-launch, a broader commercial roll-out together with Gents is planned to take place towards the end of January 2026.The production and delivery of the first commercial batch represent a major milestone for Coegin and a clear proof of the Company's transition from development to commercial operations. It confirms that Coegin's technology, production setup, and supply chain are now fully operational at commercial scale."This is an important and very gratifying milestone for Coegin," says Jens Eriksson, CEO of Coegin Pharma. Delivering our first commercial batch to Gents shows that we are now executing on our strategy, turning strong science into market-ready products. Selling out the entire pre-order batch within days is a powerful validation of both the product and the demand we are seeing. With additional deliveries already lined up, we are well positioned to accelerate our commercial roll-out."In parallel, commercial momentum continues to build. The Company expects its next delivery to take place already next week, to Hårklinikken, further strengthening Coegin's presence in professional and premium distribution channels.&nbsp;"We now have a validated product, an industrialized production process, and an expanding partner network. This places Coegin in a strong position as we move into the next phase of growth," Eriksson adds.Coegin continues to work actively with both existing and potential partners across selected markets, with the ambition to establish Follicopeptide as a leading science-based solution in premium hair growth segment.For further information, please contact: Jens Eriksson, CEO, Coegin Pharma AB Email: <a href="mailto:je@coeginpharma.com">je@coeginpharma.com</a>About Coegin Pharma Coegin Pharma is a Swedish biotech company with cutting-edge innovations for hair and skin. The company is currently commercializing its patented hair growth innovation Follicopeptide® on a global scale. In development is NPP-4, a next-generation peptide that represents a novel approach to regulating skin pigmentation through advanced biotechnology.Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.More information - including subscription to company updates and links to social media - is available at <a href="https://www.coeginpharma.com/">coeginpharma.com</a></div><div class="bequoted-files">Attached files<a rel="noopener" href="https://cdn.bequoted.com/media/1/9a3c9af1-93d6-4395-81cf-6c239cc7c8c7/251212-Press-release.pdf">251212-Press-release.pdf</a> </div>

Coegin Pharma delivers first commercial batch of Follicopeptide products to Gents